School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Division of Gastroenterology, Institute of Digestive Disease, Qingyuan People's Hospital, The Affiliated Qingyuan Hospital of Guangzhou Medical University, Qingyuan, Guangdong, China.
Front Endocrinol (Lausanne). 2024 May 17;15:1408312. doi: 10.3389/fendo.2024.1408312. eCollection 2024.
Pancreatic cancer is difficult to diagnose early and progresses rapidly. Researchers have found that a cytokine called Interleukin-6 (IL-6) is involved in the entire course of pancreatic cancer, promoting its occurrence and development. From the earliest stages of pancreatic intraepithelial neoplasia to the invasion and metastasis of pancreatic cancer cells and the appearance of tumor cachexia, IL-6 drives oncogenic signal transduction pathways and immune escape that accelerate disease progression. IL-6 is considered a biomarker for pancreatic cancer diagnosis and prognosis, as well as a potential target for treatment. IL-6 antibodies are currently being explored as a hot topic in oncology. This article aims to systematically explain how IL-6 induces the deterioration of normal pancreatic cells, with the goal of finding a breakthrough in pancreatic cancer diagnosis and treatment.
胰腺癌早期诊断困难且进展迅速。研究人员发现，一种细胞因子白细胞介素-6（IL-6）参与了胰腺癌的整个过程，促进了其发生和发展。从胰腺上皮内瘤变的最早阶段到胰腺癌细胞的侵袭和转移以及肿瘤恶病质的出现，IL-6驱动致癌信号转导途径和免疫逃逸，加速疾病进展。IL-6 被认为是胰腺癌诊断和预后的生物标志物，也是治疗的潜在靶点。IL-6 抗体目前是肿瘤学研究的热点。本文旨在系统阐述 IL-6 如何诱导正常胰腺细胞恶化，以期在胰腺癌的诊断和治疗方面取得突破。
